We thank Blanco et al. ([@B1]) for their letter on our article, which confirmed the utility of high-sensitivity C-reactive protein (hs-CRP) as a clinical biomarker to discriminate patients with HNF1A-MODY from patients with type 2 diabetes ([@B2]).

We agree with the authors that the discrimination between HNF1A-MODY and type 2 diabetes is likely to be enhanced by elevated levels of hs-CRP in type 2 diabetes as a result of mild chronic inflammation and fatty liver in combination with the unique mechanism of decreased levels of CRP expression in HNF1A-MODY. This is consistent with our findings that hs-CRP has the greatest clinical utility to distinguish between HNF1A-MODY and type 2 diabetes than between other diabetes subgroups ([@B2]--[@B4]).

Since the initial article by Owen et al. ([@B3]), these results have been replicated in over 700 patients with confirmed HNF1A-MODY across nine European centers using five different hs-CRP analytical platforms. All of these studies found that hs-CRP distinguished HNF1A-MODY from type 2 diabetes with a high diagnostic accuracy, with the C-statistic ranging from 0.79 to 0.97 ([@B2]--[@B5]). These results indicate that hs-CRP is a robust test that can be used to aid in the identification of HNF1A-MODY patients. The wide availability and low-cost of the hs-CRP test means it could be readily used in routine clinical practice.
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